Publication:
Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays

dc.contributor.authorAtsushi Yamanakaen_US
dc.contributor.authorRyosuke Suzukien_US
dc.contributor.authorEiji Konishien_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherOsaka Universityen_US
dc.contributor.otherNational Institute of Infectious Diseasesen_US
dc.date.accessioned2018-11-09T01:51:32Z
dc.date.available2018-11-09T01:51:32Z
dc.date.issued2014-07-23en_US
dc.description.abstractDengue fever and dengue hemorrhagic fever are endemic throughout tropical and subtropical countries. Four serotypes of dengue viruses (DENV-1 to DENV-4), each with several genotypes including various subclades, are co-distributed in most endemic areas. Infection-neutralizing and -enhancing antibodies are believed to play protective and pathogenic roles, respectively. Measurement of these functional antibodies against a variety of viral strains is thus important for evaluating coverage and safety of dengue vaccine candidates. Although transportation of live virus materials beyond national borders is increasingly limited, this difficulty may be overcome using biotechnology that enables generation of an antibody-assay antigen equivalent to authentic virus based on viral sequence information. A rapid system to produce flavivirus single-round infectious particles (SRIPs) was recently developed using a Japanese encephalitis virus (JEV) subgenomic replicon plasmid. This system allows production of chimeric SRIPs that have surface proteins of other flaviviruses. In the present study, SRIPs of DENV-1 (D1-SRIPs) were evaluated as an antigen for functional antibody assays. Inclusion of the whole mature capsid gene of JEV into the replicon plasmid provided higher D1-SRIP yields than did its exclusion in cases where a DENV-1 surface-protein-expressing plasmid was used for co-transfection of 293T cells with the replicon plasmid. In an assay to measure the balance between neutralizing and enhancing activities, dose (antibody dilution)-dependent activity curves in dengue-immune human sera or mouse monoclonal antibodies obtained using D1-SRIP antigen were equivalent to those obtained using DENV-1 antigen. Similar results were obtained using additional DENV-2 and DENV-3 systems. In a conventional Vero-cell neutralization test, a significant correlation was shown between antibody titers obtained using D1-SRIP and DENV-1 antigens. These results demonstrate the utility of D1-SRIPs as an alternative antigen to authentic DENV-1 in functional antibody assays. SRIP antigens may contribute to dengue vaccine candidate evaluation, understanding of dengue pathogenesis, and development of serodiagnostic systems. © 2014 Elsevier Ltd.en_US
dc.identifier.citationVaccine. Vol.32, No.34 (2014), 4289-4295en_US
dc.identifier.doi10.1016/j.vaccine.2014.06.017en_US
dc.identifier.issn18732518en_US
dc.identifier.issn0264410Xen_US
dc.identifier.other2-s2.0-84903819462en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/33241
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84903819462&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.subjectVeterinaryen_US
dc.titleEvaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assaysen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84903819462&origin=inwarden_US

Files

Collections